Gentium Signs License and Distribution Agreement for Defibrotide With Medison Pharma Ltd. in Israel and the Palestinian Authority

Gentium S.p.A. (Nasdaq: GENT) announced that the Company has signed a ten-year exclusive license and distribution agreement with Medison Pharma Ltd. for defibrotide in Israel and the Palestinian Authority. Under the terms of the agreement, Medison will be responsible for managing the named-patient sales program and for local registration, authorization, marketing, reimbursement, and medical affairs in Israel and the Palestinian Authority region. Following approval to market defibrotide, if any, Medison will have the exclusive right to promote, purchase, market and sell defibrotide in these territories.

Commenting on the appointment of Medison, Adrian Haigh, Senior Vice President of Commercial Operations said, "I am delighted that Gentium has entered into a long-term partnership with Medison, a company with a very strong presence in Oncology and Hematology and a track record of success in the Israeli market." 

Medison Pharma's President & CEO Meir Jakobsohn commented, "Medison's mission is to deliver the most innovative and unique healthcare solutions to our patients and we are very pleased to expand our Oncology & Hematology portfolio with defibrotide. Defibrotide is a unique product that addresses an unmet medical need, the treatment and prevention of veno-occlusive disease. It offers the real possibility to save lives where no alternative treatment exists."